Relmada Therapeutics Inc
F:4E2
Relmada Therapeutics Inc
F:4E2
Price:
5.3
EUR
-6.19%
Market Closed
Market Cap:
€159.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Relmada Therapeutics Inc
F:4E2
|
US |
|
O
|
Oil India Ltd
BSE:533106
|
IN |
|
A
|
Air China Ltd
LSE:AIRC
|
CN |
|
H
|
Hovnanian Enterprises Inc
OTC:HOVVB
|
US |
Balance Sheet
Balance Sheet Decomposition
Relmada Therapeutics Inc
Relmada Therapeutics Inc
Balance Sheet Decomposition is not available for
Relmada Therapeutics Inc
Relmada Therapeutics Inc
Balance Sheet
Relmada Therapeutics Inc
Relmada Therapeutics Inc
Currency: USD
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
36
|
3
|
44
|
5
|
4
|
4
|
3
|
|
| Cash Equivalents |
36
|
3
|
44
|
5
|
4
|
4
|
3
|
|
| Short-Term Investments |
80
|
115
|
168
|
143
|
92
|
41
|
90
|
|
| Total Receivables |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
11
|
4
|
1
|
1
|
1
|
|
| Total Current Assets |
117
|
118
|
223
|
153
|
98
|
46
|
94
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
117
N/A
|
118
+1%
|
223
+89%
|
153
-32%
|
98
-36%
|
46
-53%
|
94
+105%
|
|
| Liabilities | ||||||||
| Accounts Payable |
1
|
8
|
11
|
5
|
4
|
4
|
2
|
|
| Accrued Liabilities |
1
|
4
|
4
|
7
|
9
|
6
|
5
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
2
|
13
|
15
|
13
|
12
|
10
|
6
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Liabilities |
2
N/A
|
13
+740%
|
15
+20%
|
13
-17%
|
12
-2%
|
10
-16%
|
7
-27%
|
|
| Equity | ||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
120
|
179
|
305
|
462
|
561
|
641
|
698
|
|
| Additional Paid In Capital |
236
|
285
|
513
|
603
|
646
|
676
|
785
|
|
| Total Equity |
116
N/A
|
106
-9%
|
208
+97%
|
140
-33%
|
85
-39%
|
36
-58%
|
87
+144%
|
|
| Total Liabilities & Equity |
117
N/A
|
118
+1%
|
223
+89%
|
153
-32%
|
98
-36%
|
46
-53%
|
94
+105%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
15
|
16
|
28
|
30
|
30
|
30
|
73
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Other Relmada Therapeutics Inc listings:
Discover More
